TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06205667

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computer Guided Arthrocentesis
Description: patients are going to be injected intra-articular within the superior joint space of the affected TMJ through custom guided template planned in a manner inspired by earphone design to get support from the tragus.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Arthrocentesis
Description: patients are going to be injected intra-articular within the superior joint space of the affected TMJ using conventional method anatomical landmark determination
Study: NCT05506566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-FAP-CHX
Description: 68Ga-FAP-CHX, the dose will be 0.05 (mCi / kg) +/- 10% given intravenously at a single time prior to imaging； 68Ga-FAPI-04, the dose will be 1.8 (MBq / kg) +/- 10% given intravenously at a single time prior to imaging； 18F-FDG, the dose will be 3.7 (MBq / kg) +/- 10% given intravenously at a single time prior to imaging；
Study: NCT06389838

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kranus Mictera
Description: An app-based digital therapy program aimed at multimodal self-treatment for incontinence. The app is certified class I medical device (MDR).
Study: NCT06360939

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Delivery of 25Gy in a single dose fraction to target area within 6 weeks of randomization

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CA
Description: CA (endocardial and/or epicardial at operator discretion) within 6 weeks of randomization.
Study: NCT05152680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-NV-5138
Description: Single dose, given as oral solution, 1600 mg
Study: NCT06099626

Intervention type: OTHER
Intervention: Different types of disease
Description: Groups were observed according to disease type

Intervention type: OTHER
Intervention: Different types of disease
Description: Groups were observed according to disease type

Intervention type: OTHER
Intervention: Different types of disease
Description: Groups were observed according to disease type

Intervention type: OTHER
Intervention: Different types of disease
Description: Groups were observed according to disease type

Intervention type: OTHER
Intervention: Different types of disease
Description: Groups were observed according to disease type
Study: NCT06398327

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PULPOTOMY TREATMENT
Description: During pulpotomy treatment, a bleeding sample was taken from the pulp and levels of presepsin, IL-6 and IL-8, which are important inflammation markers, were determined. During the treatment, MTA, Neo MTA, Biodentine and ZOE groups were randomly selected and the remaining pulp tissue was covered. After pulpotomy treatment, the teeth were followed for one year. Treatment success was evaluated according to the material used in teeth with high levels of inflammation at the beginning.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PULPOTOMY TREATMENT
Description: During pulpotomy treatment, a bleeding sample was taken from the pulp and levels of presepsin, IL-6 and IL-8, which are important inflammation markers, were determined. During the treatment, MTA, Neo MTA, Biodentine and ZOE groups were randomly selected and the remaining pulp tissue was covered. After pulpotomy treatment, the teeth were followed for one year. Treatment success was evaluated according to the material used in teeth with high levels of inflammation at the beginning.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PULPOTOMY TREATMENT
Description: During pulpotomy treatment, a bleeding sample was taken from the pulp and levels of presepsin, IL-6 and IL-8, which are important inflammation markers, were determined. During the treatment, MTA, Neo MTA, Biodentine and ZOE groups were randomly selected and the remaining pulp tissue was covered. After pulpotomy treatment, the teeth were followed for one year. Treatment success was evaluated according to the material used in teeth with high levels of inflammation at the beginning.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PULPOTOMY TREATMENT
Description: During pulpotomy treatment, a bleeding sample was taken from the pulp and levels of presepsin, IL-6 and IL-8, which are important inflammation markers, were determined. During the treatment, MTA, Neo MTA, Biodentine and ZOE groups were randomly selected and the remaining pulp tissue was covered. After pulpotomy treatment, the teeth were followed for one year. Treatment success was evaluated according to the material used in teeth with high levels of inflammation at the beginning.
Study: NCT02866565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adipose-derived regenerative cells (ADRCs)
Description: injection of the experimental treatment
Study: NCT05060328

Intervention type: OTHER
Intervention: Medical Device Usage and Evaluation
Description: Use Google Translate Conversation Mode translation application.

Intervention type: OTHER
Intervention: Survey Administration
Description: Complete survey
Study: NCT05861336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Losartan will be administered at the dose of 25 mg PO qd starting on Cycle 1 Day 1. If this dose will be tolerated during week 1, escalation to 50 mg PO qd at Cycle 1 Day 8
Study: NCT06290583

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Spinal anesthesia with standard dose of bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prilocaine
Description: Spinal anesthesia with 50 mg dose of Prilocaine.
Study: NCT05861336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m2 on days 1, 8 and 15 every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: nab-paclitaxel 125 mg/m2 on days 1, 8, and 15

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: 7 consecutive fractions for a total dose of 35-42 Gy
Study: NCT05112965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered as a monotherapy or atezolizumab with other agent(s) as per parent protocol. Dosing regimen will continue in accordance with the parent study or at equivalent dose (if applicable) and at the same schedule as the parent study at the time of participant discontinuation from the parent study closure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered as a monotherapy or atezolizumab with other agent(s) as per parent protocol. Dosing regimen will continue in accordance with the parent study or at equivalent dose (if applicable) and at the same schedule as the parent study at the time of participant discontinuation from the parent study closure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered as directed per the parent study.
Study: NCT04222998

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based growth charts
Description: The growth chart contains simple information of nutritious food, health, and sanitation information at the top and height chart is located at the bottom where caregivers can measure their child's linear growth. Growth charts will be installed in intervention group homes just after the baseline survey.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home visits for baseline surveys
Description: Households will be visited for baseline surveys.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home visits for baseline surveys
Description: Households will be visited for baseline surveys.
Study: NCT05112965

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab will be administered as directed per the parent study.
Study: NCT06388785

Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study.
Study: NCT06546566

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Game-Based Breathing Exercises
Description: The video game-based breathing exercises program will consist of 5 breathing games included in the BreathingLabs game kit and each game will be performed in 2 sets of 10 repetitions. The program will last for 8 weeks, 5 days a week, 30 minutes a day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Breathing Exercises
Description: The conventional breathing exercises program will consist of routine breathing exercises. Breathing exercises will be given 2 times a day, 5 repetitions, 2 sets. The program will last for 8 weeks, 5 days a week, 30 minutes a day.
Study: NCT05083871

Intervention type: OTHER
Intervention: European Trauma Course
Description: Structured learning program specifically focused on Trauma management. The course provides frontal lessons, workshops for the technical skills and simulated scenarios.~Please see https://www.erc.edu/courses/european-trauma-course for additional details
Study: NCT06377358

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tecar Therapy
Description: Tecar Therapy at 1Mhz radiofrequency by the use of a C-400 device. The duration of the treatment will be 5 weeks, where 10 sessions will be carried out, 2 per week
Study: NCT05628623

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Arm A: CBF-Cytarabine 3000 mg/m2 or 1500 mg/m2 IV twice daily (BID), 12 hours apart x 6 doses either on Days 1, 3, and 5 OR Days 1, 2, and 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Arm A: CBF-Cytarabine 3000 mg/m2 or 1500 mg/m2 IV twice daily (BID), 12 hours apart x 6 doses either on Days 1, 3, and 5 OR Days 1, 2, and 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax 100 mg daily Day 1 through Day 8 Venetoclax 400 mg orally once daily on Days 1-14 Venetoclax 400 mg orally once daily on Days 1-28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax 100 mg daily Day 1 through Day 8 Venetoclax 400 mg orally once daily on Days 1-14 Venetoclax 400 mg orally once daily on Days 1-28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax 100 mg daily Day 1 through Day 8 Venetoclax 400 mg orally once daily on Days 1-14 Venetoclax 400 mg orally once daily on Days 1-28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-351
Description: Daunorubicin 29 mg/m2/Cytarabine 65 mg/m2 liposome IV on Days 1 and 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine 75 mg/m2 IV/SC on Days 1-7 OR Days 1-5 and Days 8-9 (per institutional preference)
Study: NCT05436821

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auricular vagus nerve stimulation
Description: Autonomic nerve system regulation
Study: NCT05112965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed will be administered as directed per the parent study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed will be administered as directed per the parent study.
Study: NCT05436821

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Auricular Vagus Nerve Stimulation (AVNS)
Description: Sham Auricular Vagus Nerve Stimulation (AVNS)
Study: NCT05267574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REN001
Description: Once daily dosing
Study: NCT05947552

Intervention type: DRUG
Intervention: Serum ferritin
Description: Serum ferritin in CKD patients
Study: NCT06256250

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulpectomy treatment will be done using the adaptive xp endo shaper.
Description: the patient will be anesthetized by local anesthesia. the rubber dam will be used for isolation. caries will be removed using high speed handpiece. determination of working length using apex locator. the canal patency will be checked with a # 10 K file, and gliding path until #15 K- file. the root canals of primary molars will be cleaned and shaped in pulpectomy treatment using the adaptive xp endo shaper. it is single file technique saves time and help with patient cooperation . the endomotor will be activated at aspeed of 800 rpm and 1 Ncm torque. the canals will be irrigated using 2.5% Nacol ending with 0.9% normal saline canal irrigation. the canals will be dried with paper points and obturated with Metapex. teeth will be restored by glass ionomer restoration than stainless steel crown.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulpectomy treatment will be done using FANTA AF baby files.
Description: the patient will be anesthetized by local anesthesia. the rubber dam will be used for isolation. caries will be removed using high speed handpiece. determination of working length using apex locator. The canal patency will be checked with a #10 K-file, and a glide path until #15 K-file will be created .the root canals of primary molars will be cleaned and shaped in pulpectomy treatment using FANTA AF baby files. it is pediatric rotary system consists of 4 files specialized for primary molars.Open file: #17, taper 08.~* BTF1: #20, taper 04, Yellow~* BTF2: #25, taper 04, Red~* BTF3: #30, taper 04, Blue The file will be activated at speed 350 rpm and torque 2 N until reaching the full working length. the canals will be irrigated using 2.5% Nacol ending with 0.9% normal saline canal irrigation. the canals will be dried with paper points and obturated with Metapex. teeth will be restored by glass ionomer restoration than stainless steel crown.
Study: NCT05112965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered as directed per the parent study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel will be administered as directed per the parent study.
Study: NCT06256250

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pulpectomy treatment will be done using hand k files.
Description: the patient will be anesthetized by local anesthesia. the rubber dam will be used for isolation. caries will be removed using high speed handpiece. determination of working length using apex locator. the root canals of primary molars will be cleaned and shaped in pulpectomy treatment using hand k files starting with #15 stainless steel hand K file. they are manual files, they are standard for root canal treatment (control group). the canals will be irrigated using 2.5% Nacol ending with 0.9% normal saline canal irrigation. the canals will be dried with paper points and obturated with Metapex. teeth will be restored by glass ionomer restoration than stainless steel crown.
Study: NCT04222998

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home visits for end line surveys
Description: Households will be revisited after 1 year of grace-period for baseline end line surveys.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home visits for end line surveys
Description: Households will be revisited after 1 year of grace-period for baseline end line surveys.
Study: NCT05112965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide will be administered as directed per the parent study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: Enzalutamide will be administered as directed per the parent study.
Study: NCT04577755

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo x-ray imaging
Study: NCT06529016

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Luminopia, a virtual reality headset
Description: Subjects will be provided with the equipment to use in their homes for six hours usage per week (1 hour 6 days a week), for 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paper pre- survey
Description: Pre-survey to be completed by the parent and child. Questions may be skipped. Survey developed by the study team

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paper Survey
Description: Post-survey to be completed by the parent and child. Questions may be skipped. Survey developed by the study team
Study: NCT05245071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tusamitamab ravtansine
Description: Pharmaceutical Form: Concentrate for solution Route of Administration: Intravenous infusion
Study: NCT04222998

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Measurement of child's height-for-age and weight-for-age
Description: The child's height-for-age and weight-for-age will be measured for participating dyads at the time of the baseline and end line surveys.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measurement of child's height-for-age and weight-for-age
Description: The child's height-for-age and weight-for-age will be measured for participating dyads at the time of the baseline and end line surveys.
Study: NCT04861350

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: motor imagery with action observation
Description: Standing clamshell exercise with elastic band, sliding, and Romanian deadlift exercise will be instructed to the subjects with video, and they will practice each exercise for 3 times in physical to familiarize with the program. Then, the subjects will mentally simulate each exercise with video 10 times for a set, 3 sets totally. With 2 min interval between each sets, it will take approximately 8 minutes to finish each movement. It will also take 3 min for resting between each program.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical training
Description: Standing clamshell exercise with elastic band, sliding, and Romanian deadlift exercise will be instructed to the subjects with video, and they will practice each exercise for 3 times in physical to familiarize with the program. Then, the subjects will physically perform each exercise with supervision of investigator 10 times for a set, 3 sets totally. With 2 min interval between each sets, it will take approximately 8 minutes to finish each movement. It will also take 3 min for resting between each program.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: combine physical training and motor imagery with action observation
Description: Standing clamshell exercise with elastic band, sliding, and Romanian deadlift exercise will be instructed to the subjects with video, and they will practice each exercise for 3 times in physical to familiarize with the program. Then, each exercises will be mentally simulated with video for a set and physically performed with supervision of investigator for 2 sets, 10 times for each set and 3 sets totally. With 2 min interval between each sets, it will take approximately 8 minutes to finish each movement. It will also take 3 min for resting between each program.
Study: NCT05713877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Study drug will be given at 21:00 daily, starting on the day of enrolment until delirium resolution, hospital discharge, death, or up to 14 days. The study medication will be given by mouth (PO or per os) or, if needed, via the feeding tube.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study drug will be given at 21:00 daily, starting on the day of enrolment until delirium resolution, hospital discharge, death, or up to 14 days. The study medication will be given by mouth (PO or per os) or, if needed, via the feeding tube.
Study: NCT06116942

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active rTMS
Description: The Transcranial Magnetic Stimulation will consist of placing a figure-of-eight shape coil of wire over the head of the participants. Then, a brief electric current will pass through the coil, inducing a magnetic field capable of stimulating neurons located beneath the coil. For the active coil, the maximal stimulation intensity is reached beneath the center of the coil.~In the present study, the intermittent theta-burst protocol will be implemented. This protocol is expected to modulate the excitability of the brain, priming it for a stronger activation of the motor-related brain areas engaged during brain-computer interface-based training. The structural MRI of each participant will be used to guide neuronavigation towards ipsilesional motor areas.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active rTMS
Description: The Transcranial Magnetic Stimulation will consist of placing a figure-of-eight shape coil of wire over the head of the participants. Then, a brief electric current will pass through the coil, inducing a magnetic field capable of stimulating neurons located beneath the coil. For the active coil, the maximal stimulation intensity is reached beneath the center of the coil.~In the present study, the intermittent theta-burst protocol will be implemented. This protocol is expected to modulate the excitability of the brain, priming it for a stronger activation of the motor-related brain areas engaged during brain-computer interface-based training. The structural MRI of each participant will be used to guide neuronavigation towards ipsilesional motor areas.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham rTMS
Description: To implement a placebo stimulation, a sham coil will be used to deliver the same stimulation protocol. The sham coil is identical in dimensions and weight to the active coil but produces a diminished magnetic field. For the sham coil, the stimulation intensity is minimal beneath the center of the coil, the same area with the highest intensity during stimulation with an active coil. The structural MRI scan of each participant will be used to guide neuronavigation towards the same area where the active stimulation was applied.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham rTMS
Description: To implement a placebo stimulation, a sham coil will be used to deliver the same stimulation protocol. The sham coil is identical in dimensions and weight to the active coil but produces a diminished magnetic field. For the sham coil, the stimulation intensity is minimal beneath the center of the coil, the same area with the highest intensity during stimulation with an active coil. The structural MRI scan of each participant will be used to guide neuronavigation towards the same area where the active stimulation was applied.
Study: NCT05464966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose insulin potassium
Description: After induction of anaesthesia,cardiac systolic-diastolic function was first measured by TEE, GIK solution was continuously pumped until the end of the procedure at a dose of 30 mU/kg/h of insulin, 0.12 g/kg/h of glucose and 0.06 mmol/kg/h of potassium chloride
Study: NCT05396040

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LOLLI METHODE
Description: WEEKLY SCREENING WITH POOLED SALIVA PCR TEST